Shenfu Injection Adjunct with Platinum-Based Chemotherapy for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review

Table 1

Baseline characteristics of included studies.

Study	N (T/C)	Physical	Stage	Interventions		Outcomes
				T	C
Liang et al., 2016 [18]	39/39	KPS ≥ 60	III-IV	DP + SFI (80 ml/d, d1–d10)	DP	⑦
Wang et al., 2016 [19]	96/96	PS ≤ 2	IIIb-IV	GP + SFI (100 ml/d, d1–d15)	GP	①②③④⑤
Zhang, 2015 [20]	64/64	NR	III-IV	GP + SFI (60 ml/d, d1–d21)	GP	①⑦
Xie et al., 2015 [21]	40/40	PS ≤ 2	III-IV	TP + SFI (80 ml/d, d1–d7)	TP	②④⑤
Bai et al., 2014 [22]	39/39	KPS ≥ 60	III-IV	DP + SFI (80 ml/d, d1–d10)	DP	①②③④⑤⑥
Li, 2014 [23]	30/30	PS ≤ 2	III-IV	NP + SFI (50 ml/d, d1–d10)	NP	①⑥
Chen and Zhao, 2013 [24]	40/36	KPS ≥ 60	IIIb-IV	GP + SFI (30 ml/d, d1–d14)	GP	②④⑤
Gao et al., 2008 [25]	43/43	KPS ≥ 60	III-IV	GP + SFI (60 ml/d, d1–d10)	GP	①②③④⑤⑥
Hu, 2011 [26]	19/19	PS ≤ 2	III-IV	GP + SFI (60 ml/d, d1–d9)	GP	②③④
Jiang et al., 2011 [27]	38/38	KPS ≥ 60	III-IV	NP + SFI (60 ml/d, d1–d10)	NP	⑦
Liu and Huang, 2011 [28]	30/30	KPS ≥ 70	III-IV	NP + SFI (60 ml/d, d1–d14)	NP	⑥
Lu et al., 2011 [29]	30/30	KPS ≥ 60	III-IV	NP + SFI (60 ml/d, d1–d10)	NP	①②④⑤⑦
Liu and Zhang, 2010 [30]	18/19	PS ≤ 2	IIIb-IV	TP + SFI (60 ml/d, d1–d14)	TP	①②③④⑤
Chen, 2010 [31]	24/23	NR	III-IV	NP + SFI (50 ml/d, d1–d10)	NP	①②③④⑤
Xie et al., 2010 [32]	25/25	KPS ≥ 60	III-IV	NP + SFI (50 ml/d, 1–d10)	NP	②③④⑤
Zhang et al., 2009 [33]	31/28	KPS ≥ 60	IIIb-IV	GC + SFI (60 ml/d, d1–d10)	GC	①②③④⑤⑦
Liu, 2008 [34]	21/20	KPS ≥ 60	III-IV	GP + SFI (50 ml/d, d1–d10)	GP	②③④⑤
Li et al., 2008 [35]	26/28	KPS ≥ 70	IIIb-IV	TC + SFI (100 ml/d, d1–d7)	TC	①
Tang et al., 2008 [36]	18/19	KPS ≥ 60	IIIb-IV	NP + SFI (60 ml/d, d1–d7)	NP	①⑤⑥
Liu et al., 2008 [37]	35/35	PS ≤ 2	IIIb-IV	TP + SFI (40–60 ml/d, d1–d10)	TP	⑦
Gong and Luo, 2008 [38]	30/30	KPS ≥ 50	IIIb-IV	NP + SFI (50 ml/d, d1–d14)	NP	①②③④
Lu et al., 2005 [39]	36/29	KPS ≥ 60	IIIb-IV	TP + SFI (50 ml/d, d1–d14)	TP	②③④
Liu et al., 2004 [40]	21/21	KPS ≥ 60	IIIb-IV	NP + SFI (50 ml/d, d1–d14)	NP	①②④

N, number of participants; T, treatment; C, control; KPS, Karnofsky performance score; PS, performance status; SFI, Shenfu injection; NR, not reported; DP, docetaxel + platinum; GP, gemcitabine + platinum; TP, taxol + platinum; NP, navelbine + platinum; GC, gemcitabine + cisplatin; TC, taxol + cisplatin; ① objective tumor response; ② white blood cell toxicity; ③ hemoglobin toxicity; ④ platelet toxicity; ⑤ vomiting toxicity; ⑥ KPS; ⑦ immune function.